SRR8518212
— · D
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- D
- subtype
- D
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ALLOGRAFT_REJECTION+0.540
- INTERFERON_GAMMA_RESPONSE+0.530
- INTERFERON_ALPHA_RESPONSE+0.440
- COMPLEMENT+0.390
- IL6_JAK_STAT3_SIGNALING+0.390
- IL2_STAT5_SIGNALING+0.350
- INFLAMMATORY_RESPONSE+0.320
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.280
- PANCREAS_BETA_CELLS+0.270
- PI3K_AKT_MTOR_SIGNALING+0.230
Top 10 suppressed
- NOTCH_SIGNALING-0.410
- CHOLESTEROL_HOMEOSTASIS-0.330
- WNT_BETA_CATENIN_SIGNALING-0.300
- ESTROGEN_RESPONSE_EARLY-0.280
- ESTROGEN_RESPONSE_LATE-0.250
- GLYCOLYSIS-0.230
- MYOGENESIS-0.230
- HEDGEHOG_SIGNALING-0.200
- KRAS_SIGNALING_DN-0.190
- ANGIOGENESIS-0.170
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR8518123 | — | D | 0.860 |
| 2 | BSR_02_0049_A5_S69 | — | D | 0.856 |
| 3 | SRR8518312 | — | D | 0.844 |
| 4 | SRR8518190 | — | D | 0.834 |
| 5 | SAMN03290949 | — | — | 0.824 |
| 6 | 20090401.Her2HRpos | — | D | 0.819 |
| 7 | SRR8613787 | — | D | 0.818 |
| 8 | a0fad25f-74d8-42f1-8e47-4d56c091e000 | — | — | 0.811 |
| 9 | ERR2208965 | — | — | 0.802 |
| 10 | TCGA-75-5122-01A-01R-1755-07 | — | cohortA1 | 0.801 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 26 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ALLOGRAFT_REJECTION | 0.540 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.530 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.440 | Inavolisib | — uncovered |
| COMPLEMENT | 0.390 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.390 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.350 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.320 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.280 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.270 | Cobimetinib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.230 | Inavolisib | — uncovered |
| APOPTOSIS | 0.210 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.170 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.160 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.160 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.150 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.140 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.110 | Temsirolimus | — uncovered |
| PROTEIN_SECRETION | 0.110 | Remibrutinib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.100 | Remibrutinib | — uncovered |
| PEROXISOME | 0.080 | Idelalisib | — uncovered |